atgl

Atglistatin is a highly effective, specific and competitive ATGL inhibitor with an IC50 of ~0.7 μM for inhibition of lipolysis in vitro, and no toxicity when the concentration up to 50 μM.

Y-320 is a new phenylpyrazoleanilide immunomodulator.

NG-497 is a selective, small molecule inhibitor of human adipose triglyceride lipase (ATGL) that targets the enzymatically active patatin-like structural domain of human ATGL.NG-497 binds ATGL in a hydrophobic lumen adjacent to the active site.NG-497 abrogates lipolysis in human adipocytes in a dose-dependent and reversible manner.NG-497 has been shown to be useful in cancer research. can be used in cancer research.

COP1-ATGL modulator 1 (86) is an orally active compound that targets the COP1-ATGL axis. It enhances ATGL protein expression, decreases ATGL ubiquitination and COP1 autoubiquitination, and notably reduces lipid accumulation in hepatocytes, effective in the nanomolar concentration [1].

Glucuronokinase (AtGlcAK), a GHMP-kinase family member, displays exclusive substrate specificity for D-glucuronic acid, evidenced by a K m of 0.7 mM. It catalyzes the transformation of D-glucuronic acid and ATP into D-glucuronic acid-1-phosphate and ADP [1].